Two gout experts debated whether first-line urate-lowering therapy should consist of a xanthine oxidase inhibitor or should ...

The presentation highlights XORTX recent pioneering discoveries in the field of Autosomal Dominant Polycystic Kidney Disease (“ADPKD”), and recent peer-reviewed, independent, published research ...

Febuxostat is a promising inhibitor of xanthine oxidase that has yet to be studied as a secondary preventative measure for either uric acid nephrolithiasis or for hyperuricosuric calcium stone ...

XORTX Therapeutics (XRTX) announces a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, ...